{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:06:39Z","timestamp":1793743599082,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-025-00333-6","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:55:21Z","timestamp":1744199721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Investigating cardiovascular diseases related to endocrine therapy in hormone receptor-positive early breast cancer: insights from a nationwide real-world study"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9392-8259","authenticated-orcid":false,"given":"Cheng","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenna","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9432-1902","authenticated-orcid":false,"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"333_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41571-024-00935-6","volume":"21","author":"MR Lloyd","year":"2024","unstructured":"Lloyd MR, Jhaveri K, Kalinsky K, Bardia A, Wander SA. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol. 2024;21:743\u201361. https:\/\/doi.org\/10.1038\/s41571-024-00935-6","journal-title":"Nat Rev Clin Oncol"},{"key":"333_CR2","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Gnant M. Breast cancer. Lancet (London. England). 2017;389:1134\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(16)31891-8","journal-title":"England)"},{"key":"333_CR3","doi-asserted-by":"publisher","unstructured":"Zhai J, Wu Y, Ma F, Kaklamani V, Xu B. Advances in medical treatment of breast cancer in 2022. Cancer Innov. 2023;2. https:\/\/doi.org\/10.1002\/cai2.46","DOI":"10.1002\/cai2.46"},{"key":"333_CR4","doi-asserted-by":"publisher","unstructured":"Patel HK, Bihani T. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol Ther. 2018;186. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.12.012","DOI":"10.1016\/j.pharmthera.2017.12.012"},{"key":"333_CR5","doi-asserted-by":"publisher","first-page":"102624","DOI":"10.1016\/j.ctrv.2023.102624","volume":"120","author":"L Cucciniello","year":"2023","unstructured":"Cucciniello L, Garufi G, Di Rienzo R, Martinelli C, Pavone G, Giuliano M, et al. Estrogen deprivation effects of endocrine therapy in breast cancer patients: incidence, management and outcome. Cancer Treat Rev. 2023;120:102624. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102624","journal-title":"Cancer Treat Rev"},{"key":"333_CR6","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1530\/JOE-19-0077","volume":"241","author":"SK Ramchand","year":"2019","unstructured":"Ramchand SK, Cheung Y-M, Yeo B, Grossmann M. The effects of adjuvant endocrine therapy on bone health in women with breast cancer. J Endocrinol. 2019;241:R111. https:\/\/doi.org\/10.1530\/JOE-19-0077","journal-title":"J Endocrinol"},{"key":"333_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.breast.2020.08.003","volume":"54","author":"SH Choi","year":"2020","unstructured":"Choi SH, Kim K-E, Park Y, Ju YW, Jung J-G, Lee ES, et al. Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: an analysis of nationwide data. Breast. 2020;54:25\u201330. https:\/\/doi.org\/10.1016\/j.breast.2020.08.003","journal-title":"Breast"},{"key":"333_CR8","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","volume":"93","author":"B Fisher","year":"2001","unstructured":"Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684\u201390. https:\/\/doi.org\/10.1093\/jnci\/93.9.684","journal-title":"J Natl Cancer Inst"},{"key":"333_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/01.CIR.0000154545.84124.AC","volume":"111","author":"A Decensi","year":"2005","unstructured":"Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. 2005;111:650\u20136. https:\/\/doi.org\/10.1161\/01.CIR.0000154545.84124.AC","journal-title":"Circulation"},{"key":"333_CR10","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1002\/cncr.24508","volume":"115","author":"RK Hernandez","year":"2009","unstructured":"Hernandez RK, S\u00f8rensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer. 2009;115:4442\u20139. https:\/\/doi.org\/10.1002\/cncr.24508","journal-title":"Cancer"},{"key":"333_CR11","doi-asserted-by":"publisher","first-page":"109087","DOI":"10.1016\/j.thromres.2024.109087","volume":"241","author":"MA P\u00e9rez-Jacoiste As\u00edn","year":"2024","unstructured":"P\u00e9rez-Jacoiste As\u00edn MA, Blanco Molina \u00c1, G\u00f3mez-Cuervo C, D\u00edaz-Pedroche MDC, Pedrajas JM, L\u00f3pez-N\u00fa\u00f1ez JJ, et al. Venous thromboembolism in women with hormone-dependent breast cancer. To continue or discontinue hormonal treatment? Insights from the RIETE registry. Thromb Res. 2024;241:109087. https:\/\/doi.org\/10.1016\/j.thromres.2024.109087","journal-title":"Thromb Res"},{"key":"333_CR12","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/jnci\/djh285","volume":"96","author":"AM Geiger","year":"2004","unstructured":"Geiger AM, Fischberg GM, Chen W, Bernstein L. Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst. 2004;96:1528\u201336. https:\/\/doi.org\/10.1093\/jnci\/djh285","journal-title":"J Natl Cancer Inst"},{"key":"333_CR13","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1161\/STROKEAHA.120.033272","volume":"52","author":"JP Marto","year":"2021","unstructured":"Marto JP, Strambo D, Livio F, Michel P. Drugs associated with ischemic stroke: a review for clinicians. Stroke. 2021;52:e646\u201359. https:\/\/doi.org\/10.1161\/STROKEAHA.120.033272","journal-title":"Stroke"},{"key":"333_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clbc.2016.07.003","volume":"17","author":"J Foglietta","year":"2017","unstructured":"Foglietta J, Inno A, de Iuliis F, Sini V, Duranti S, Turazza M, et al. Cardiotoxicity of aromatase inhibitors in breast cancer patients. Clin Breast Cancer. 2017;17:11\u20137. https:\/\/doi.org\/10.1016\/j.clbc.2016.07.003","journal-title":"Clin Breast Cancer"},{"key":"333_CR15","doi-asserted-by":"publisher","first-page":"103114","DOI":"10.1016\/j.critrevonc.2020.103114","volume":"156","author":"F Zhao","year":"2020","unstructured":"Zhao F, Ren D, Shen G, Ahmad R, Dong L, Du F, et al. Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: a systemtic review and meta-analysis. Crit Rev Oncol\/Hematol. 2020;156:103114. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103114","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"333_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40959-024-00221-5","volume":"10","author":"K Abboud","year":"2024","unstructured":"Abboud K, Umoru G, Trachtenberg B, Ajewole V. Real-world data of cardio-oncologic interventions for cardiovascular adverse events with oral oncolytics. Cardiooncology. 2024;10:22. https:\/\/doi.org\/10.1186\/s40959-024-00221-5","journal-title":"Cardiooncology"},{"key":"333_CR17","doi-asserted-by":"publisher","unstructured":"Abdel-Qadir H, Amir E, Fischer HD, Fu L, Austin PC, Harvey PJ et al. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. European Journal of Cancer (Oxford, England: 1990). 2016; 68: 11\u201321. https:\/\/doi.org\/10.1016\/j.ejca.2016.08.022","DOI":"10.1016\/j.ejca.2016.08.022"},{"key":"333_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/jcpt.13598","volume":"47","author":"Q Yu","year":"2022","unstructured":"Yu Q, Xu Y, Yu E, Zheng Z. Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: a systematic review and meta-analysis. J Clin Pharm Ther. 2022;47:575\u201387. https:\/\/doi.org\/10.1111\/jcpt.13598","journal-title":"J Clin Pharm Ther"},{"key":"333_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1161\/CIRCULATIONAHA.119.044750","volume":"141","author":"F Khosrow-Khavar","year":"2020","unstructured":"Khosrow-Khavar F, Filion KB, Bouganim N, Suissa S, Azoulay L. Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study. Circulation. 2020;141:549\u201359. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044750","journal-title":"Circulation"},{"key":"333_CR20","doi-asserted-by":"publisher","first-page":"e70548","DOI":"10.1002\/cam4.70548","volume":"14","author":"S Elshafie","year":"2025","unstructured":"Elshafie S, Villa-Zapata L, Tackett RL, Zaghloul IY, Young HN. Cardiovascular and metabolic adverse events of endocrine therapies in women with breast cancer: a disproportionality analysis of reports in the FDA adverse event reporting system. Cancer Med. 2025;14:e70548. https:\/\/doi.org\/10.1002\/cam4.70548","journal-title":"Cancer Med"},{"key":"333_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10549-020-05675-6","volume":"182","author":"L Bach","year":"2020","unstructured":"Bach L, Kostev K, Schiffmann L, Kalder M. Association between thyroid gland diseases and breast cancer: a case-control study. Breast Cancer Res Treat. 2020;182:207\u201313. https:\/\/doi.org\/10.1007\/s10549-020-05675-6","journal-title":"Breast Cancer Res Treat"},{"key":"333_CR22","doi-asserted-by":"publisher","unstructured":"2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018; https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2018.01.011","DOI":"10.11909\/j.issn.1671-5411.2018.01.011"},{"key":"333_CR23","doi-asserted-by":"publisher","first-page":"111680","DOI":"10.1016\/j.exger.2021.111680","volume":"159","author":"SA Alomar","year":"2022","unstructured":"Alomar SA, G\u0103man M-A, Prabahar K, Arafah OA, Almarshood F, Baradwan S, et al. The effect of tamoxifen on the lipid profile in women: a systematic review and meta-analysis of randomized controlled trials. Exp Gerontol. 2022;159:111680. https:\/\/doi.org\/10.1016\/j.exger.2021.111680","journal-title":"Exp Gerontol"},{"key":"333_CR24","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/annonc\/mdq707","volume":"22","author":"Y Hozumi","year":"2011","unstructured":"Hozumi Y, Suemasu K, Takei H, Aihara T, Takehara M, Saito T, et al. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National surgical adjuvant study BC 04, the TEAM Japan sub-study. Annals Oncology: Official J Eur Soc Med Oncol. 2011;22:1777\u201382. https:\/\/doi.org\/10.1093\/annonc\/mdq707","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"key":"333_CR25","doi-asserted-by":"publisher","first-page":"759595","DOI":"10.3389\/fonc.2021.759595","volume":"11","author":"Y-K Kang","year":"2021","unstructured":"Kang Y-K, Wang X, Hu N-L, Yue J, Si Y-R, Ju J, et al. The effects of endocrine therapies on lipid profiles in Chinese young women with early breast cancer. Front Oncol. 2021;11:759595. https:\/\/doi.org\/10.3389\/fonc.2021.759595","journal-title":"Front Oncol"},{"key":"333_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.phrs.2018.06.004","volume":"134","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Kishi H, Kobayashi S. Add-on therapy with traditional Chinese medicine: an efficacious approach for lipid metabolism disorders. Pharmacol Res. 2018;134:200\u201311. https:\/\/doi.org\/10.1016\/j.phrs.2018.06.004","journal-title":"Pharmacol Res"},{"key":"333_CR27","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1016\/j.jacc.2017.04.041","volume":"69","author":"P Hao","year":"2017","unstructured":"Hao P, Jiang F, Cheng J, Ma L, Zhang Y, Zhao Y. Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms. J Am Coll Cardiol. 2017;69:2952\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.041","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00333-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00333-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00333-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T23:04:04Z","timestamp":1744239844000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-025-00333-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00333-6","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Independent Ethics Committee of the National Cancer Center\/Cancer Hospital (Approval number: 21\/369\u20133040). All procedure were performed in accordance with the Declaration of Helsinki and the International Conference for Harmonization\/Good Clinical Practice guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}